首页> 美国卫生研究院文献>Cancer Science >Monitoring of cancer patients via next‐generation sequencing of patient‐derived circulating tumor cells and tumor DNA
【2h】

Monitoring of cancer patients via next‐generation sequencing of patient‐derived circulating tumor cells and tumor DNA

机译:通过患者源循环肿瘤细胞和肿瘤DNA的下一代测序监测癌症患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Liquid biopsy of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) is gaining attention as a method for real‐time monitoring in cancer patients. Conventional methods based upon epithelial cell adhesion molecule (EpCAM) expression have a risk of missing the most aggressive CTC subpopulations due to epithelial‐mesenchymal transition and may, thus, underestimate the total number of actual CTC present in the bloodstream. Techniques utilizing a label‐free inertial microfluidics approach (LFIMA) enable efficient capture of CTC without the need for EpCAM expression. In this study, we optimized a method for analyzing genetic alterations using next‐generation sequencing (NGS) of extracted ctDNA and CTC enriched using an LFIMA as a first‐phase examination of 30 patients with head and neck cancer, esophageal cancer, gastric cancer and colorectal cancer (CRC). Seven patients with advanced CRC were enrolled in the second‐phase examination to monitor the emergence of alterations occurring during treatment with epidermal growth factor receptor (EGFR)‐specific antibodies. Using style="fixed-case">LFIMA, we effectively captured style="fixed-case">CTC (median number of style="fixed-case">CTC, 14.5 cells/mL) from several types of cancer and detected missense mutations via style="fixed-case">NGS of style="fixed-case">CTC and ct style="fixed-case">DNA. We also detected time‐dependent genetic alterations that appeared during anti– style="fixed-case">EGFR therapy in style="fixed-case">CTC and ct style="fixed-case">DNA from style="fixed-case">CRC patients. The results of style="fixed-case">NGS analyses indicated that alterations in the genomic profile revealed by the liquid biopsy could be expanded by using a combination of assays with style="fixed-case">CTC and ct style="fixed-case">DNA. The study was registered with the University Hospital Medical Information Network Clinical Trials Registry ( style="fixed-case">ID: style="fixed-case"> UMIN000014095).
机译:循环肿瘤细胞(CTC)和循环肿瘤DNA(ctDNA)的液体活检作为癌症患者实时监测的一种方法正受到关注。基于上皮细胞粘附分子(EpCAM)表达的常规方法由于上皮-间质转化而有可能错过最具攻击性的CTC亚群,因此可能低估了血液中实际CTC的总数。利用无标记惯性微流控方法(LFIMA)的技术可有效捕获CTC,而无需EpCAM表达。在这项研究中,我们优化了一种方法,该方法利用提取的ctDNA和CTC的下一代测序(NGS)进行了分析,该方法使用LFIMA进行了富集,作为30例头颈癌,食道癌,胃癌和大肠癌(CRC)。七名晚期CRC的患者参加了第二阶段检查,以监测表皮生长因子受体(EGFR)特异性抗体治疗期间出现的变化。使用 style =“ fixed-case”> LFIMA ,我们有效地捕获了 style =“ fixed-case”> CTC ( style =“ fixed-case”> CTC的中位数,14.5细胞/ mL),并通过 style =“ fixed-case”> CTC NGS 检测到错义突变>和ct style =“ fixed-case”> DNA 。我们还检测了在 style =“ fixed-case”> CTC 和ct style的抗 style =“ fixed-case”> EGFR 治疗期间出现的时间依赖性遗传改变来自 style =“ fixed-case”> CRC 患者的=“ fixed-case”> DNA 。 style =“ fixed-case”> NGS 分析的结果表明,通过结合使用 style =“ fixed-case”的检测方法,可以扩大液体活检所揭示的基因组谱变化。 > CTC 和ct style =“ fixed-case”> DNA 。该研究已在大学医院医学信息网络临床试验注册中心( style =“ fixed-case”> ID : style =“ fixed-case”> UMIN 000014095)注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号